Repros gets the nod to proceed in clinical trials

The FDA notifies Repros Therapeutics (RPRX) that it may proceed with phase 1 and phase 2 studies for Proellex under separate INDs for endometriosis and uterine fibroids while remaining on partial clinical hold.

The maximum allowed dose will be 12 mg daily.

Consensus 2015 revenue estimate is $16.8M.

133 mutual funds have positions, up from 120 a year earlier.

From other sites
Comments (1)
    , contributor
    Comment (1) | Send Message
    Good news for shareholders! Expecting a .10 jump by end of March 2014.
    17 Mar 2014, 02:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs